Properties of bcr-abl-transformed mouse 12B1 cells secreting interleukin-2 and granulocyte-macrophage colony-stimulating factor: I. Derivation, genetic stability, oncogenicity and immunogenicity

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1668-1676

  Petráčková, Martina ^a   Tachezy, Ruth ^a   Vonka, Vladimír ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Bcr abl; Chronic myeloid leukaemia; Gene modified cells; Immunogenicity; Pathogenicity

Indexed keywords

BCR ABL PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INACTIVATED VACCINE; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CARCINOGENICITY; CELL CLONE; CELL INFILTRATION; CELL POPULATION; CELL SECRETION; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC RESISTANCE; GENETIC STABILITY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IMMUNOGENICITY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE; PATHOGENICITY; PLASMID; PRIORITY JOURNAL; PROTEIN SECRETION; SECRETORY CELL; SOLID TUMOR; TUMOR REGRESSION;

ANIMALS; BLOTTING, WESTERN; CANCER VACCINES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; LEUKEMIA; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR BURDEN;

EID: 84860296173     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1365     Document Type: Article

References (37)

1. Orchard PJ, Katsanis E, Boyer M, May C, McIvor RS and Blazar BR: Interleukin-2 secretion by transduced and unselected BDL-2 lymphoma results in increased survival in mice with previously established disseminated disease. Cancer Biother Radiopharm 11: 155-164, 1996. (Pubitemid 26178078)
2. Tung C, Federoff HJ, Brownlee M, Karpoff H, Weigel T, Brennan MF and Fong Y: Rapid production of interleukin- 2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum Gene Ther 7: 2217-2224, 1996. (Pubitemid 27021456)
3. Rodolfo M, Zilocchi C, Melani C, Cappetti B, Arioli I, Parmiani G and Colombo MP: Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 157: 5536-5542, 1996. (Pubitemid 126448975)
4. Van EA, Aarnoudse C, van der Minne CE, van der Spek CW, Brouwenstijn N, Osanto S and Schrier PI: Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. J Immunother 20: 343-353, 1997. (Pubitemid 28011530)
5. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R and Heller R: In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 10: 577-583, 2000. (Pubitemid 32011981)
6. Mazzocchi A, Melani C, Rivoltini L, et al: Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunol Immunother 50: 199-211, 2001. (Pubitemid 32662402)
7. Ge NL, Ye SL, Zheng N, Sun RX, Liu YK and Tang ZY: Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines. World J Gastroenterol 9: 2182-2185, 2003. (Pubitemid 37321441)
8. Jinoch P, Zak R, Janouskova O, et al: Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2. Int J Oncol 23: 775-783, 2003.
9. Indrova M, Bubenik J, Mikyskova R, et al: Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int J Oncol 22: 691-695, 2003.
10. Sobotkova E, Duskova M, Smahel M, Holan V, Janouskova O and Vonka V: Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells. Oncol Rep 12: 877-883, 2004.
11. Rittich S, Duskova M, Mackova J, Pokorna D, Jinoch P and Smahel M: Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol Rep 13: 311-317, 2005.
12. Sobotkova E, Duskova M, Eckschlager T and Vonka V: Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells. Int J Oncol 33: 421-426, 2008.
13. Sobotkova E, Duskova M, Tachezy R, Petrackova M and Vonka V: Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells. Oncol Rep 21: 793-799, 2009.
14. Rossowska J, Pajtasz-Piasecka E, Rysnik O, Wojas J, Krawczenko A, Szyda A and Dus D: Generation of antitumor response by IL-2-transduced JAWS II dendritic cells. Immunobiology 216: 1074-1084, 2011.
15. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993. (Pubitemid 23111402)
16. Eager R and Nemunaitis J: GM-CSF gene-transduced tumor vaccines. Mol Ther 12: 18-27, 2005. (Pubitemid 40862352)
17. Le DT, Pardoll DM and Jaffee EM: Cellular vaccine approaches. Cancer J 16: 304-310, 2010.
18. Gupta R and Emens LA: GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 10: 52-60, 2010.
19. Vonka V: Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2: 227-241, 2010.
20. Borrello IM, Levitsky HI, Stock W, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 114: 1736-1745, 2009.
21. Ho VT, Vanneman M, Kim H, et al: Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 106: 15825-15830, 2009.
22. Zilberberg J, Friedman TM, Dranoff G and Korngold R: Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice. Biol Blood Marrow Transplant 17: 330-340, 2011.
23. Smith BD, Kasamon YL, Kowalski J, et al: K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 16: 338-347, 2010.
24. Lucansky V, Sobotkova E, Tachezy R, Duskova M and Vonka V: DNA vaccination against bcr-abl-positive cells in mice. Int J Oncol 35: 941-951, 2009.
25. Hruskova V, Moravkova A, Babiarova K, Ludvikova V, Fric J, Vonka V and Forstova J: Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles. Int J Oncol 35: 1247-1256, 2009.
26. Petrackova M, Sobotkova E, Duskova M, Jinoch P and Vonka V: Isolation and properties of gene-modified mouse bcr-abl-transformed cells expressing various immunostimulatory factors. Neoplasma 56: 194-201, 2009.
27. McLaughlin J, Chianese E and Witte ON: In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84: 6558-6562, 1987.
28. Sobotkova E, Ludvikova V, Petrackova M, et al: Characteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells. Folia Biol (Praha) 51: 12-18, 2005. (Pubitemid 40372916)
29. Jelinek F, Sobotkova E and Vonka V: Characteristics of two mouse bcr-abl-transformed cell lines. II. Pathological lesions induced in mice. Folia Biol (Praha) 51: 93-102, 2005. (Pubitemid 41300834)
30. Smahel M, Sima P, Ludvikova V and Vonka V: Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells. Virology 281: 231-238, 2001. (Pubitemid 32881139)
31. Rossner P, Bubenik J, Sobota V, et al: Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines. Folia Biol (Praha) 45: 173-177, 1999. (Pubitemid 29433556)
32. Zolotukhin S, Potter M, Hauswirth WW, Guy J and Muzyczka N: A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70: 4646-4654, 1996.
33. Petráčková M, Stanêk L, Mandys V, Dundr P and Vonka V: Properties of bcr-abl-transformed mouse 12B1 cells secreting interleukin-2 and granulocyte-macrophage colony stimulating factor: II. Adverse effects of GM-CSF. Int J Oncol (In press).
34. Chorna I, Bilyy R, Datsyuk L and Stoika R: Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin: effect of ionizing radiation on apoptosis and TGF-beta production. Exp Oncol 26: 111-117, 2004.
35. Davis-Sproul JM, Harris MP, Davidson NE, Kobrin BJ, Jaffee EM and Emens LA: Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. Cytotherapy 7: 46-56, 2005. (Pubitemid 40542403)
36. Rosenthal FM, Kulmburg P, Fruh R, et al: Systemic hematological effects of granulocyte colony-stimulating factor produced by irradiated gene-transfected fibroblasts. Hum Gene Ther 7: 2147-2156, 1996. (Pubitemid 26400739)
37. Jaffee EM and Pardoll DM: Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 12: 143-153, 1997. (Pubitemid 27241370)